SG11201607339VA - Methods and compositions for modulating estrogen receptor mutants - Google Patents
Methods and compositions for modulating estrogen receptor mutantsInfo
- Publication number
- SG11201607339VA SG11201607339VA SG11201607339VA SG11201607339VA SG11201607339VA SG 11201607339V A SG11201607339V A SG 11201607339VA SG 11201607339V A SG11201607339V A SG 11201607339VA SG 11201607339V A SG11201607339V A SG 11201607339VA SG 11201607339V A SG11201607339V A SG 11201607339VA
- Authority
- SG
- Singapore
- Prior art keywords
- compositions
- methods
- estrogen receptor
- receptor mutants
- modulating estrogen
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Pathology (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physics & Mathematics (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Hospice & Palliative Care (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyrane Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461952728P | 2014-03-13 | 2014-03-13 | |
| US201461981708P | 2014-04-18 | 2014-04-18 | |
| PCT/EP2015/055120 WO2015136017A1 (fr) | 2014-03-13 | 2015-03-12 | Méthodes et compositions pour moduler des mutants du récepteur des oestrogènes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201607339VA true SG11201607339VA (en) | 2016-10-28 |
Family
ID=52682706
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201607339VA SG11201607339VA (en) | 2014-03-13 | 2015-03-12 | Methods and compositions for modulating estrogen receptor mutants |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US9855270B2 (fr) |
| EP (1) | EP3116496A1 (fr) |
| JP (1) | JP2017509631A (fr) |
| KR (1) | KR20160132029A (fr) |
| CN (1) | CN106488767A (fr) |
| AU (1) | AU2015228860A1 (fr) |
| BR (1) | BR112016020953A2 (fr) |
| CA (1) | CA2941161A1 (fr) |
| IL (1) | IL247250A0 (fr) |
| MA (1) | MA39740A (fr) |
| MX (1) | MX2016011698A (fr) |
| RU (1) | RU2016137150A (fr) |
| SG (1) | SG11201607339VA (fr) |
| WO (1) | WO2015136017A1 (fr) |
Families Citing this family (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2804624B1 (fr) | 2012-01-19 | 2018-12-26 | Duke University | Vaccins dirigés contre des antigènes impliqués dans la résistance à un traitement et leurs méthodes d'utilisation |
| US9586952B2 (en) | 2013-03-14 | 2017-03-07 | Genentech, Inc. | Polycyclic estrogen receptor modulators and uses thereof |
| MX2015016171A (es) | 2013-06-19 | 2016-08-08 | Seragon Pharmaceuticals Inc | Moduladores del receptor de estrogeno de azetidina y usos de los mismos. |
| SG11201509508YA (en) | 2013-06-19 | 2015-12-30 | Seragon Pharmaceuticals Inc | Estrogen receptor modulator and uses thereof |
| CA2927752A1 (fr) * | 2013-10-18 | 2015-04-23 | The Regents Of The University Of Michigan | Systemes et procedes permettant de determiner un plan therapeutique d'action |
| EP3166646A4 (fr) | 2014-07-07 | 2018-03-07 | Duke University | Vaccins contre un isoforme oncogène d'her2 (erbb2) et leurs méthodes d'utilisation |
| EP3166630A4 (fr) * | 2014-07-07 | 2018-03-28 | Duke University | Vaccins dirigés contre une isoforme oncogène d'esr1 et leurs méthodes d'utilisation |
| AR101487A1 (es) | 2014-08-11 | 2016-12-21 | Hoffmann La Roche | Formas cristalinas de un modulador de receptor de estrógeno |
| MA53837A (fr) | 2014-12-18 | 2021-11-10 | Hoffmann La Roche | Tetrahydro-pyrido[3,4-b]indoles modulateurs des récepteurs des oestrogènes et leurs utilisations |
| EP3233828B1 (fr) | 2014-12-18 | 2020-03-04 | F. Hoffmann-La Roche AG | Modulateurs des recepteurs des oestrogenes et leurs utilisations |
| EP3274476B1 (fr) | 2015-03-25 | 2023-06-07 | The General Hospital Corporation | Analyse numérique de cellules tumorales circulantes dans des échantillons de sang |
| JP6768711B2 (ja) | 2015-05-26 | 2020-10-14 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | 複素環式エストロゲン受容体モジュレーター及びその使用 |
| US9975856B2 (en) | 2015-10-07 | 2018-05-22 | Genentech, Inc. | Process for the preparation of (E)-3-(4-((E)-2-(2-chloro-4-fluorophenyl)-1-(1H-indazol-5-yl)but-1-en-1-yl)phenyl)acrylic acid |
| EP3386500B1 (fr) | 2015-12-09 | 2022-09-07 | The Board of Trustees of the University of Illinois | Répresseurs du récepteur oestrogénique sélectifs à base de benzothiophène |
| WO2017120576A1 (fr) * | 2016-01-07 | 2017-07-13 | Duke University | Vaccins contre le cancer et méthodes d'administration |
| ES2842579T3 (es) * | 2016-02-05 | 2021-07-14 | Inventisbio Llc | Degradadores de los receptores de estrógenos selectivos y sus usos |
| PE20181953A1 (es) | 2016-03-02 | 2018-12-17 | Eisai Randd Man Co Ltd | Conjugados de anticuerpo y farmaco basados en eribulina y metodos para su uso |
| AU2017239348B2 (en) * | 2016-03-25 | 2020-03-12 | Luoxin Healthcare Science and Technology Development (Beijing) Ltd. | Substituted-indole compounds as estrogen receptor down-regulators |
| US11459617B2 (en) | 2016-04-29 | 2022-10-04 | Board Of Regents, The University Of Texas System | Targeted measure of transcriptional activity related to hormone receptors |
| TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療 |
| TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
| US20180002344A1 (en) | 2016-06-16 | 2018-01-04 | Genentech, Inc. | Heteroaryl estrogen receptor modulators and uses thereof |
| US10695450B2 (en) | 2016-07-26 | 2020-06-30 | Laboratoires Cyclopharma | Synthesis of a radioactive agent composition |
| EP3500681B1 (fr) * | 2016-08-18 | 2021-01-20 | Roche Diagnostics GmbH | Dosages pcr multiplex spécifiques à des allèles pour la détection de mutations du récepteur d'oestrogènes esr1 |
| CN107814798B (zh) * | 2016-09-14 | 2020-11-03 | 四川科伦博泰生物医药股份有限公司 | 3-取代丙烯酸类化合物及其制备方法和用途 |
| US11224665B2 (en) | 2016-10-05 | 2022-01-18 | Duke University | Mitochondrial antiviral signaling (MAVS) protein compositions and methods of using the same |
| US10487143B2 (en) | 2016-10-05 | 2019-11-26 | Duke University | Vaccines against HER3 antigens and methods of using the same |
| WO2018071440A1 (fr) * | 2016-10-11 | 2018-04-19 | Duke University | Traitement du cancer du sein |
| WO2018081168A2 (fr) | 2016-10-24 | 2018-05-03 | The Board Of Trustees Of The University Of Illinois | Répresseurs du récepteur oestrogénique sélectifs mixtes à base de benzothiophène |
| EP3532642B1 (fr) * | 2016-10-27 | 2021-12-08 | The General Hospital Corporation | Analyse numérique d'échantillons de sang pour déterminer l'efficacité de thérapies anticancéreuses pour des cancers spécifiques |
| JP7229162B2 (ja) | 2017-01-06 | 2023-02-27 | ジー１ セラピューティクス， インコーポレイテッド | 癌の治療に対する併用療法 |
| CN110461853A (zh) | 2017-02-10 | 2019-11-15 | G1治疗公司 | 苯并噻吩雌激素受体调节剂 |
| WO2019023481A1 (fr) * | 2017-07-28 | 2019-01-31 | Zeno Royalties & Milestones, LLC | Analogues de l'acide acrylique |
| US11034653B2 (en) | 2017-09-25 | 2021-06-15 | Luoxin Pharmaceutical (Shanghai) Co., Ltd. | Crystal form of estrogen receptor inhibitor and preparation method therefor |
| AU2018368731A1 (en) | 2017-11-16 | 2020-05-14 | Novartis Ag | Combination therapies |
| SG11202006147SA (en) * | 2017-12-27 | 2020-07-29 | Tesaro Inc | Methods of treating cancer |
| CN117771239A (zh) | 2018-04-10 | 2024-03-29 | 杜克大学 | 乳腺癌的拉索昔芬治疗 |
| JP6916969B1 (ja) | 2018-06-21 | 2021-08-11 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | ３−（（１Ｒ，３Ｒ）−１−（２，６−ジフルオロ−４−（（１−（３−フルオロプロピル）アゼチジン−３−イル）アミノ）フェニル）−３−メチル−１，３，４，９−テトラヒドロ−２Ｈ−ピリド［３，４−ｂ］インドール−２−イル）−２，２−ジフルオロプロパン−１−オールの固体形態及び置換されたフェニル又はピリジニル部分を含む縮合三環式化合物を調製するための方法とそれらの使用方法 |
| AR116109A1 (es) | 2018-07-10 | 2021-03-31 | Novartis Ag | Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos |
| CN111184863B (zh) * | 2018-11-15 | 2023-06-16 | 江苏恒瑞医药股份有限公司 | 酪氨酸激酶抑制剂、cdk4/6抑制剂、serd联合在制备治疗肿瘤的药物中的用途 |
| CN113166056A (zh) * | 2018-11-28 | 2021-07-23 | 罗欣药业(上海)有限公司 | 一种雌激素受体下调剂的盐型、晶型及其制备方法 |
| AU2019402189B2 (en) | 2018-12-20 | 2023-04-13 | Novartis Ag | Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives |
| EP3902545A4 (fr) | 2018-12-24 | 2022-06-22 | InventisBio Co., Ltd. | Nouveaux sels d'agents de dégradation sélectifs du récepteur des oestrogènes |
| BR112021015672A2 (pt) | 2019-02-15 | 2021-10-05 | Novartis Ag | Derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona substituída e usos dos mesmos |
| BR112021015783A2 (pt) | 2019-02-15 | 2021-10-05 | Novartis Ag | Derivados de 3-(1-oxo-5-(piperidin-4-il)isoindolin-2-il)piperidina-2,6-diona e usos dos mesmos |
| US20230081720A1 (en) | 2019-05-20 | 2023-03-16 | Novartis Ag | Mcl-1 inhibitor antibody-drug conjugates and methods of use |
| CN110982807B (zh) * | 2019-12-17 | 2022-04-29 | 云南农业大学 | 一种高效稳定的纤维素酶突变体 |
| KR20220116257A (ko) | 2019-12-20 | 2022-08-22 | 노파르티스 아게 | 골수섬유증 및 골수이형성 증후군을 치료하기 위한, 데시타빈 또는 항 pd-1 항체 스파르탈리주맙을 포함하거나 또는 포함하지 않는, 항 tim-3 항체 mbg453 및 항 tgf-베타 항체 nis793의 조합물 |
| CA3169679A1 (fr) * | 2020-03-06 | 2021-09-10 | Olema Pharmaceuticals, Inc. | Methodes de traitement de maladies associees au recepteur des strogenes |
| US20230348459A1 (en) * | 2020-05-15 | 2023-11-02 | Simcere Pharmaceutical Co., Ltd. | Pyrrolidine compound and use thereof |
| CN115916199A (zh) | 2020-06-23 | 2023-04-04 | 诺华股份有限公司 | 包含3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物的给药方案 |
| JP2023536164A (ja) | 2020-08-03 | 2023-08-23 | ノバルティス アーゲー | ヘテロアリール置換３－（１－オキソイソインドリン－２－イル）ピペリジン－２，６－ジオン誘導体及びその使用 |
| JP2023553808A (ja) | 2020-11-24 | 2023-12-26 | ノバルティス アーゲー | Ｍｃｌ－１阻害剤抗体－薬物コンジュゲートおよび使用方法 |
| MX2023006010A (es) | 2020-11-24 | 2023-06-08 | Novartis Ag | Anticuerpos anti-cd48, conjugados de anticuerpo-farmaco, y usos de los mismos. |
| CA3206906A1 (fr) | 2021-02-02 | 2022-08-11 | Andras Herner | Composes bcl-xl protac selectifs et procedes d'utilisation |
| TW202304979A (zh) | 2021-04-07 | 2023-02-01 | 瑞士商諾華公司 | 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途 |
| WO2022245124A1 (fr) * | 2021-05-18 | 2022-11-24 | 재단법인 대구경북첨단의료산업진흥재단 | Nouveau composé d'éthène et composition pharmaceutique le comprenant en tant que principe actif pour la prévention ou le traitement du cancer |
| AR125874A1 (es) | 2021-05-18 | 2023-08-23 | Novartis Ag | Terapias de combinación |
| CN113293213A (zh) * | 2021-06-17 | 2021-08-24 | 深圳华因康基因科技有限公司 | 一种检测乳腺癌复发转移基因her2扩增的引物探针及其应用 |
| WO2023225320A1 (fr) | 2022-05-20 | 2023-11-23 | Novartis Ag | Conjugués anticorps-médicament inhibiteurs de bcl-xl et méthodes d'utilisation associées |
| WO2023225336A1 (fr) | 2022-05-20 | 2023-11-23 | Novartis Ag | Conjugués anticorps-médicament inhibiteurs de met bcl-xl et leurs procédés d'utilisation |
| WO2024033513A1 (fr) | 2022-08-11 | 2024-02-15 | Diaccurate | Composés pour le traitement du cancer |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6060503A (en) * | 1991-12-02 | 2000-05-09 | Endorecherche, Inc. | Benzopyran-containing compounds and method for their use |
| DE60035522T2 (de) | 1999-12-07 | 2008-03-20 | Sumitomo Chemical Co., Ltd. | Mutant er-alpha und nachweissysteme für transaktivierung |
| EP3205648A1 (fr) | 2010-06-10 | 2017-08-16 | Seragon Pharmaceuticals, Inc. | Modulateur du récepteur oestrogénique et utilisation de ces derniers |
| GB2483736B (en) | 2010-09-16 | 2012-08-29 | Aragon Pharmaceuticals Inc | Estrogen receptor modulators and uses thereof |
| WO2013056178A2 (fr) * | 2011-10-14 | 2013-04-18 | Foundation Medicine, Inc. | Nouvelles mutations de récepteur des estrogènes et leurs utilisations |
| WO2013090829A1 (fr) * | 2011-12-14 | 2013-06-20 | Aragon Pharmaceuticals, Inc. | Modulateurs des récepteurs des œstrogènes et ses utilisations |
| JP2015505856A (ja) * | 2011-12-16 | 2015-02-26 | オレマ ファーマシューティカルズ インク． | 新規のベンゾピラン化合物、その組成物および使用 |
| SG11201405918XA (en) | 2012-03-20 | 2014-10-30 | Seragon Pharmaceuticals Inc | Estrogen receptor modulators and uses thereof |
| US9586952B2 (en) * | 2013-03-14 | 2017-03-07 | Genentech, Inc. | Polycyclic estrogen receptor modulators and uses thereof |
| AU2014274730A1 (en) * | 2013-06-07 | 2016-01-21 | Rana Therapeutics, Inc. | Compositions and methods for modulating FOXP3 expression |
| EP3004381A1 (fr) * | 2013-06-07 | 2016-04-13 | Keygene N.V. | Méthode de séquençage ciblé |
| SG11201509508YA (en) | 2013-06-19 | 2015-12-30 | Seragon Pharmaceuticals Inc | Estrogen receptor modulator and uses thereof |
| MX2015016171A (es) | 2013-06-19 | 2016-08-08 | Seragon Pharmaceuticals Inc | Moduladores del receptor de estrogeno de azetidina y usos de los mismos. |
| EP3089747A1 (fr) | 2013-12-06 | 2016-11-09 | F. Hoffmann-La Roche AG | Modulateur du récepteur des strogènes pour le traitement du cancer du sein localement avancé ou positif aux récepteurs des strogènes métastatiques |
| MX2016011636A (es) | 2014-03-13 | 2016-12-12 | Hoffmann La Roche | Combinaciones terapeuticas con moduladores de receptor de estrogeno. |
-
2015
- 2015-03-12 EP EP15709908.6A patent/EP3116496A1/fr not_active Withdrawn
- 2015-03-12 MX MX2016011698A patent/MX2016011698A/es unknown
- 2015-03-12 CN CN201580025224.0A patent/CN106488767A/zh active Pending
- 2015-03-12 KR KR1020167025197A patent/KR20160132029A/ko unknown
- 2015-03-12 RU RU2016137150A patent/RU2016137150A/ru not_active Application Discontinuation
- 2015-03-12 SG SG11201607339VA patent/SG11201607339VA/en unknown
- 2015-03-12 CA CA2941161A patent/CA2941161A1/fr not_active Abandoned
- 2015-03-12 BR BR112016020953A patent/BR112016020953A2/pt not_active Application Discontinuation
- 2015-03-12 MA MA039740A patent/MA39740A/fr unknown
- 2015-03-12 JP JP2016557076A patent/JP2017509631A/ja active Pending
- 2015-03-12 US US14/645,578 patent/US9855270B2/en not_active Expired - Fee Related
- 2015-03-12 WO PCT/EP2015/055120 patent/WO2015136017A1/fr active Application Filing
- 2015-03-12 AU AU2015228860A patent/AU2015228860A1/en not_active Abandoned
-
2016
- 2016-08-11 IL IL247250A patent/IL247250A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US9855270B2 (en) | 2018-01-02 |
| EP3116496A1 (fr) | 2017-01-18 |
| CN106488767A (zh) | 2017-03-08 |
| KR20160132029A (ko) | 2016-11-16 |
| RU2016137150A (ru) | 2018-04-18 |
| MA39740A (fr) | 2017-01-18 |
| MX2016011698A (es) | 2016-12-12 |
| WO2015136017A1 (fr) | 2015-09-17 |
| BR112016020953A2 (pt) | 2018-01-23 |
| AU2015228860A1 (en) | 2016-09-08 |
| CA2941161A1 (fr) | 2015-09-17 |
| RU2016137150A3 (fr) | 2018-10-19 |
| US20150258099A1 (en) | 2015-09-17 |
| JP2017509631A (ja) | 2017-04-06 |
| IL247250A0 (en) | 2016-09-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL247250A0 (en) | Methods and compositions for modulating estrogen receptor mutants | |
| HK1247199A1 (zh) | 雌激素受體調節劑及其用途 | |
| IL273058A (en) | Compositions and methods for modulation of PKK expression | |
| HK1257295A1 (zh) | 用於免疫腫瘤學的組合物和方法 | |
| IL272653A (en) | Preparations and methods for the modulation of growth hormone receptor expression | |
| HK1243333A1 (zh) | 用於修飾的t細胞的方法和組合物 | |
| IL249373A0 (en) | Polypeptide formulations of related detector and method | |
| IL271659A (en) | Compositions and methods for modulating expression of complement factor B | |
| EP3183349A4 (fr) | Procédés de préparation de rébaudioside i et utilisations associées | |
| IL246879A0 (en) | Preparations of Epilimod and methods of using them | |
| EP3212315A4 (fr) | Compositions et méthodes de formation d'émulsions | |
| GB201507781D0 (en) | Blending techniques for curve fitting | |
| IL268684A (en) | Preparations and methods for immuno-oncology | |
| GB201417828D0 (en) | New methods and compositions | |
| EP3094323A4 (fr) | Méthodes et compositions pour moduler les taux d'hormone | |
| IL274524A (en) | Preparations and methods for aquaculture | |
| EP3137624A4 (fr) | Compositions et procédés pour la modulation de mtorc1 | |
| IL249203B (en) | Androgen receptor modulators and methods of using them | |
| SG11201702475VA (en) | Methods and compositions for modulating th-gm cell function | |
| EP3227249A4 (fr) | Compositions et procédés permettant l'introduction de micronutriments | |
| PL3113774T3 (pl) | Kompozycje grapiprantu i sposoby ich zastosowania | |
| EP3224230A4 (fr) | Modulateurs du récepteur des strogènes | |
| GB201405403D0 (en) | Receptor modulation |